{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.660","value":"1.46"}]}],"title":"Baseline (n = 2037)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.692","value":"1.04"}]}],"title":"Week 24 (n = 2008)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.693","value":"0.97"}]}],"title":"Week 48 (n = 1853)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.694","value":"0.89"}]}],"title":"Week 108 (n = 1635)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.689","value":"0.87"}]}],"title":"Week 156 (n = 1529)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.684","value":"0.84"}]}],"title":"Week 204 (n = 1438)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.696","value":"0.86"}]}],"title":"Week 264 (n = 1334)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2067"}],"units":"Participants"}],"description":"The Health Assessment Questionnaire-Disability Index (HAQ-DI), as a measure of functional ability, consists of 30 questions in 8 domains: Dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. There are 4 possible responses to each question (0=without any difficulty, 1=with some difficulty, 2=with much difficulty, 3=unable to do). A domain score is the highest score in that domain. To calculate the overall score, the patient must have a domain score in at least 6 of the 8 domains. The HAQ-DI score is the sum of the domain scores divided by the number of domains that have a non-missing score and ranges from 0 (best) to 3 (worst). A higher score indicates less ability.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"MEAN","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants with available data were included in the analysis.","timeFrame":"Baseline to Week 264","title":"Health Assessment Questionnaire-Disability Index Score at Baseline and Weeks 24, 48, 108, 156, 204, and 264","type":"SECONDARY","unitOfMeasure":"Units on a scale"}